4SC Past Earnings Performance
Past criteria checks 0/6
4SC has been growing earnings at an average annual rate of 10.2%, while the Biotechs industry saw earnings growing at 15.3% annually. Revenues have been declining at an average rate of 7.4% per year.
Key information
10.2%
Earnings growth rate
22.1%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -7.4% |
| Return on equity | -163.0% |
| Net Margin | -2,709.5% |
| Next Earnings Update | 08 Aug 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How 4SC makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -8 | 2 | 0 |
| 30 Sep 23 | 0 | -8 | 2 | 0 |
| 30 Jun 23 | 0 | -8 | 2 | 0 |
| 31 Mar 23 | 0 | -11 | 3 | 0 |
| 31 Dec 22 | 0 | -14 | 4 | 0 |
| 30 Sep 22 | 0 | -19 | 4 | 0 |
| 30 Jun 22 | 0 | -23 | 5 | 0 |
| 31 Mar 22 | 7 | -16 | 5 | 0 |
| 31 Dec 21 | 14 | -10 | 5 | 0 |
| 30 Sep 21 | 15 | -8 | 4 | 5 |
| 30 Jun 21 | 16 | -7 | 4 | 9 |
| 31 Mar 21 | 9 | -13 | 3 | 14 |
| 31 Dec 20 | 2 | -19 | 3 | 18 |
| 30 Sep 20 | 1 | -19 | 3 | 17 |
| 30 Jun 20 | 0 | -19 | 3 | 16 |
| 31 Mar 20 | 1 | -16 | 3 | 15 |
| 31 Dec 19 | 2 | -14 | 3 | 14 |
| 30 Sep 19 | 2 | -15 | 3 | 15 |
| 30 Jun 19 | 2 | -17 | 3 | 16 |
| 31 Mar 19 | 3 | -17 | 3 | 17 |
| 31 Dec 18 | 4 | -18 | 3 | 18 |
| 30 Sep 18 | 6 | -15 | 3 | 17 |
| 30 Jun 18 | 7 | -12 | 3 | 15 |
| 31 Mar 18 | 6 | -11 | 3 | 13 |
| 31 Dec 17 | 4 | -11 | 3 | 11 |
| 30 Jun 17 | 2 | -10 | 3 | 9 |
| 31 Mar 17 | 2 | -11 | 4 | 10 |
| 31 Dec 16 | 2 | -11 | 4 | 11 |
| 30 Jun 16 | 1 | -11 | 4 | 9 |
| 31 Mar 16 | 1 | -10 | 3 | 8 |
| 31 Dec 15 | 2 | -8 | 3 | 6 |
| 30 Sep 15 | 4 | -10 | 4 | 7 |
| 30 Jun 15 | 6 | -10 | 4 | 8 |
| 31 Mar 15 | 8 | -9 | 4 | 8 |
| 31 Dec 14 | 7 | -10 | 4 | 9 |
| 30 Sep 14 | 7 | -9 | 4 | 8 |
| 30 Jun 14 | 7 | -8 | 3 | 9 |
| 31 Mar 14 | 6 | -10 | 3 | 10 |
| 31 Dec 13 | 5 | -11 | 4 | 10 |
| 30 Sep 13 | 7 | -9 | 4 | 11 |
| 30 Jun 13 | 6 | -12 | 4 | 12 |
Quality Earnings: VSC is currently unprofitable.
Growing Profit Margin: VSC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VSC is unprofitable, but has reduced losses over the past 5 years at a rate of 10.2% per year.
Accelerating Growth: Unable to compare VSC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VSC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: VSC has a negative Return on Equity (-163.04%), as it is currently unprofitable.